3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
3
Completed
3
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Head and Neck Neoplasms
1
Interventions
telotristat ethyl
4
lutetium Lu 177 dotatate
4
3-Iodobenzylguanidine
3
vandetanib
2
pasireotide
2
gallium Ga 68 dotatate
2
Temozolomide
2
Octreotide
2
Biological Therapy
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
veliparib
1
vatalanib
1
trametinib
1
pembrolizumab
1
lanreotide
1
fosbretabulin
1
farletuzumab
1
dabrafenib
1
combretastatin
1
ceritinib
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Tretinoin
1
Tranexamic Acid
1
Solutions
1
Saline Solution
1
Panitumumab
1
Paclitaxel
1
Microarray Analysis
1
Isotretinoin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
fosbretabulin
×
Endocrine
×
Clear all
NCT01701349
2014-05-01
FACT2
Mateon Therapeutics
Phase 3
Withdrawn